BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:cadisegliatin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of cadisegliatin\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06334133-10930@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:cadisegliatin: Phase 3 readout est. (NCT06334133)
DESCRIPTION:cadisegliatin\, phase 3\, Type 1 Diabetes.\nStudy: Cadisegliati
 n as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes\nE
 stimated primary completion: April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cadisegliatin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06334133
URL:https://assetmemo.bio/drug/cadisegliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616206-10930@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:cadisegliatin: Phase 2 readout est. (NCT07616206)
DESCRIPTION:cadisegliatin\, phase 2\, Type 1 Diabetes.\nStudy: Cadisegliati
 n as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Wh
 o Are Using Hybrid Closed Loop (HCL) Systems\nEstimated primary completion
 : June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cadisegl
 iatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07616206
URL:https://assetmemo.bio/drug/cadisegliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
